STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance:  
I- 17b-Hydroxy-5-androstano[3,2-c]pyrazole  
II- 5a-N-Acetyl-2'H-androst-16-en-2-eno[3,2-c]pyrazol-17-ol Acetate  
III- 5a-N-Acetyl-2'H-androst-2-eno[3,2-c]pyrazol-17-one  
IV- (5a,16b)-N-Acetyl-16-acetyloxy-2'H-androst-2-eno[3,2-c]pyrazol-17-one  
V- (5a,16b)-N-Acetyl-16-(2-(acetyloxy)acetyloxy)-2'H-androst-2-eno[3,2-c]pyrazol-17-one

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

- Controlled ☐
- Not Controlled X

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

- The substances have not been reported to display any anabolic activity nor derived from an anabolic steroid.

Prepared by: ____________________________ Date: _______________
Vincent Marleau

Verified by: ____________________________ Date: _______________
Mark Kozlowski

Approved by: ______________________________________ Date: _______________
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: “third party information removed as per agreement with applicant”
Drug Status Report

Drugs:
I- 17b-Hydroxy-5-androstan-3,2-c]pyrazole
II- 5a-N-Acetyl-2'H-androst-16-en-2-eno[3,2-c]pyrazol-17-ol Acetate
III- 5a-N-Acetyl-2'H-androst-2-eno[3,2-c]pyrazol-17-one
IV- (5a,16b)-N-Acetyl-16-acetyloxy-2'H-androst-2-eno[3,2-c]pyrazol-17-one
V- (5a,16b)-N-Acetyl-16-(2-acetyloxy)acetyloxy)-2'H-androst-2-eno[3,2-c]pyrazol-17-one

Drug Name Status:
I- 17b-Hydroxy-5-androstan-3,2-c]pyrazole
II- 5a-N-Acetyl-2'H-androst-16-en-2-eno[3,2-c]pyrazol-17-ol Acetate
III- 5a-N-Acetyl-2'H-androst-2-eno[3,2-c]pyrazol-17-one
IV- (5a,16b)-N-Acetyl-16-acetyloxy-2'H-androst-2-eno[3,2-c]pyrazol-17-one
V- (5a,16b)-N-Acetyl-16-(2-acetyloxy)acetyloxy)-2'H-androst-2-eno[3,2-c]pyrazol-17-one are the common names.

Chemical Name:
I- (3aS,3bR,5aS,10aS,10bS,12aS)-10a,12a-dimethyl-3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1(2H)-one
II- (3aS,3bR,5aS,10aS,10bS,12aS)-7-acetyl-10a,12a-dimethyl-3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl acetate
III- (3aS,3bR,5aS,10aS,10bS,12aS)-7-acetyl-10a,12a-dimethyl-3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1(2H)-one
IV- (2S,3aS,3bR,5aS,10aS,10bS,12aS)-7-acetyl-10a,12a-dimethyl-1-oxo-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-2-yl acetate
V- (2S,3aS,3bR,5aS,10aS,10bS,12aS)-7-acetyl-10a,12a-dimethyl-1-oxo-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-2-yl 2-acetoxyacetate

Chemical structure:

![Chemical Structure I](image1)
![Chemical Structure II](image2)
![Chemical Structure III](image3)
Molecular Formula: I- C_{20}H_{28}N_{2}O; II- C_{24}H_{32}N_{2}O_{3}; III- C_{22}H_{30}N_{2}O_{2}; IV- C_{24}H_{32}N_{2}O_{4}; V- C_{26}H_{34}N_{2}O_{6}.

CAS-RN: I- 129545-93-3; II- N/A; III- N/A; IV- N/A; V- N/A.

Pharmacological class / Application: Steroids

International status:


United Nations: The substances are not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.

Canadian Status: 17b-Hydroxy-5-androstano[3,2-c]pyrazole, 5a-N-acetyl-2'H-androst-16-en-2-eno[3,2-c]pyrazol-17-ol Acetate, 5a-N-acetyl-2'H-androst-2-eno[3,2-c]pyrazol-17-one, (5a,16b)-N-acetyl-16-acetyloxy-2'H-androst-2-eno[3,2-c]pyrazol-17-one and (5a,16b)-N-acetyl-16-(2-(acetyloxy)acetyloxy)-2'H-androst-2-eno[3,2-c]pyrazol-17-one are not listed specifically in the CDSA. The substances are intermediates related to the synthesis of 16beta-hydroxy stanozolol, a metabolite of stanozolol, which is currently listed as sub-item 23(38) of Schedule IV to the CDSA under the heading “Anabolic steroids and their derivatives including:”. However since none of these steroids are derivatives of stanozolol nor reported to display any anabolic activity, they cannot be included under item 23 of Schedule IV to the CDSA.


Date: August 13th, 2012.